Simson Jake 4
4 · Janux Therapeutics, Inc. · Filed Jun 16, 2023
Insider Transaction Report
Form 4
Simson Jake
Director
Transactions
- Award
Stock Option (right to buy)
2023-06-14+12,500→ 12,500 totalExercise: $13.22Exp: 2033-06-13→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.